# Ultragenyx Pharmaceutical Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Ultragenyx Pharmaceutical Inc.). ## Overview Ultragenyx Pharmaceutical Inc. is a U.S.-based biopharmaceutical company focused on therapies for serious rare and ultra-rare genetic diseases. Its portfolio combines approved medicines and clinical-stage programs across biologics, small molecules, AAV gene therapy, and nucleic acid-based candidates, with commercialization in North America, Europe, Latin America, Türkiye, Asia, and selected international markets. ## Products & services • Crysvita® (burosumab) for XLH and TIO • Mepsevii® (vestronidase alfa) for MPS VII • Dojolvi® (triheptanoin) for LC-FAOD • Evkeeza® (evinacumab) for HoFH in Europe • Clinical pipeline: UX701, UX143, DTX401 and others - **Approved rare disease therapies** (75%) — Commercial medicines for genetically defined rare diseases such as XLH, TIO, MPS VII, LC-FAOD and HoFH. - **AAV gene therapy candidates** (15%) — Gene therapy programs aimed at correcting the underlying cause of inherited metabolic and genetic disorders. - **Biologics and antibody programs** (5%) — Protein and antibody-based therapies, including approved products and late-stage candidates. - **Small molecule and nucleic acid programs** (5%) — Non-biologic pipeline assets designed for rare disease mechanisms and targeted genetic correction. - Crysvita® (burosumab) for X-linked hypophosphatemia and TIO - Mepsevii® (vestronidase alfa) for mucopolysaccharidosis VII - Dojolvi® (triheptanoin) for long-chain fatty acid oxidation disorders - Evkeeza® (evinacumab) for homozygous familial hypercholesterolemia in Europe - Clinical pipeline in biologics, small molecules, AAV gene therapy and nucleic acids ## Customers Ultragenyx sells primarily to patients with rare genetic diseases through specialty pharmacies, distributors, and healthcare providers that diagnose and treat these conditions. Demand is driven by the need for chronic, often lifelong treatment in small patient populations where diagnosis, reimbursement, and specialist access are critical. - **Rare disease patients** (primary) — Patients with XLH, TIO, MPS VII, LC-FAOD, HoFH and other genetic disorders who use the therapies chronically. - **Specialty pharmacies** (primary) — Dispense approved products and influence ordering patterns, inventory levels and patient access. - **Commercial distributors** (secondary) — Handle product distribution in smaller international markets where Ultragenyx does not sell directly. - **Specialist physicians and treatment centers** (primary) — Diagnose rare diseases, prescribe therapies, and manage long-term treatment protocols. - **Payers and reimbursement authorities** (primary) — Approve coverage and reimbursement, which strongly affects adoption in orphan drug markets. - Patients with rare genetic diseases needing chronic therapy - Specialty pharmacies that dispense orphan drugs to patients - Commercial distributors serving smaller international markets - Hospitals and specialist physicians managing complex rare disorders - Payers and reimbursement systems that determine access and uptake ## Geography Ultragenyx commercializes its products across North America, the European Union, the United Kingdom, Latin America, Türkiye, Asia, and selected international markets. The company uses its own commercial organization in major markets and third-party distributors in smaller markets, which makes access, reimbursement, and distributor execution important to revenue realization. - Commercial presence spans North America, Europe, Latin America and Asia - Own sales organization in major markets supports rare-disease commercialization - Third-party distributors are used in smaller markets and can affect sell-through - Europe is important for Evkeeza® commercialization outside the U.S. - Geographic execution matters because orphan-drug access is highly local ## Strategy Ultragenyx focuses on in-licensing promising rare-disease assets and retaining global commercialization rights where possible. Its strategy is to run multiple clinical programs in parallel, use orphan-drug expertise to accelerate development, and build a specialized global commercial footprint for approved therapies. - **Advance multiple rare-disease programs in parallel** (medium-term) — Diversifies pipeline risk and creates several shots on goal in small markets. - **Expand and defend commercial products** (short-term) — Approved therapies fund the business and establish relationships with rare-disease specialists. - **Preserve global commercialization rights** (long-term) — Owning ex-U.S. and U.S. rights where possible increases long-term value capture. - **Leverage rare-disease development capabilities** (long-term) — Patient identification, trial design and regulatory execution are key competitive advantages in orphan drugs. - In-license rare disease assets with clear biology and unmet need - Retain global commercialization rights to maximize portfolio value - Advance multiple programs in parallel to diversify pipeline risk - Use orphan-drug expertise to improve development speed and efficiency - Build a specialized global commercial organization for approved products ## Risks Ultragenyx depends on successful commercialization of a small number of approved products and on clinical and regulatory progress across a concentrated pipeline. The business is exposed to rare-disease market size uncertainty, manufacturing and single-source supply risk, reimbursement pressure, and reliance on third parties for development, distribution and supply. - **Small addressable patient populations** [high] — Rare-disease markets are inherently limited, so patient identification and penetration are critical to revenue. - **Clinical and regulatory failure** [high] — Pipeline value depends on successful trials, endpoints, and approvals in complex orphan indications. - **Manufacturing and single-source supply disruption** [critical] — Drug substance and drug product for many products and candidates come from single-source suppliers. - **Distributor and specialty pharmacy concentration** [high] — A considerable portion of sales flows through a small number of intermediaries, affecting sell-through and inventory. - **Reimbursement and market access** [high] — Orphan drugs often require payer approval and favorable coverage to achieve broad uptake. - **Dependence on Kyowa Kirin for Crysvita in major markets** [high] — The company relies on a partner for commercialization and supply in certain markets, including the U.S. and Canada. - Small patient populations can limit market size and uptake - Clinical development and regulatory outcomes are uncertain - Single-source suppliers and CMOs create manufacturing concentration risk - Distributor and specialty pharmacy buying patterns can be volatile - Reimbursement and coverage decisions can delay adoption - Pipeline and commercial dependence on a few products increases concentration risk ## Accounting Revenue recognition is affected by reserves for rebates, chargebacks, returns and other deductions, which can materially change reported sales when estimates are revised. Investors should also watch collaboration and royalty-related obligations, manufacturing commitments, and potential milestone payments tied to development success, as these create judgment-heavy liabilities and future cash outflows. - **Revenue reserves** — Can materially affect net product revenue and period-to-period comparability - **Distributor and specialty pharmacy inventory patterns** — Can create quarter-to-quarter volatility in product revenue - **Liabilities for sales of future royalties** — Affects balance sheet liabilities and interest-like expense recognition - **Manufacturing and service contract obligations** — Can affect operating liabilities and cash outflow timing - **License and collaboration milestone payments** — Creates uncertain future obligations and potential expense recognition - Revenue reserves for rebates, chargebacks and product returns - Sales mix and distributor inventory can affect quarterly revenue timing - Future royalty liabilities depend on product sales and contractual terms - Manufacturing commitments and CMO terminations can create accruals - Milestone obligations from licenses and collaborations are uncertain --- *Last updated: 2026-04-29T05:06:06.987525+00:00*